Roflumilast as add-on therapy to conventional inhalers in COPD: A cost-effectiveness analysis

Journal of Comparative Effectiveness Research

Volumn 1, Issue 4, 2012, Pages 315-317

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

bronchodilators; chronic obstructive pulmonary disease; long acting antimuscarinic therapy; medication cost; quality adjusted life years; roflumilast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG; ROFLUMILAST; SHORT ACTING DRUG;

ADD ON THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG COST; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; MAINTENANCE THERAPY; NOTE; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION;

EID: 84886944066     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.12.31     Document Type: Note

References (3)

1. Calverley PMA, Rabe KF, Goehring U-M, Kristiansen SR, Fabbri LM, Martinez FJ. Rofumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374(9691), 685-694 (2009).
2. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental ana lysis. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 183-199 (2012).
3. Antoniu SA. Inhaled phosphodiesterase type 5 inhibitors for cystic fbrosis: a new therapy for systemic disease? Expert Opin. Investig. Drugs 20(5), 713-715 (2011).